Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mevacor-to-Lescol Switches Should Encourage Lescol 40 mg - Study

Executive Summary

Programs to substitute Novartis' Lescol (fluvastatin) for Merck's Mevacor (lovastatin) should consider using only the 40 mg dose of Lescol to avoid a significant worsening of outcomes, a study of one switch program concluded.

You may also be interested in...

APhA depression management study

American Pharmacists Association is launching a depression-management program to evaluate the effect of pharmacist-delivered medication therapy management-type services. Project ImPACT: Depression (Improving Persistence And Compliance with Therapy) will focus on whether pharmacists can improve depression treatent adherence. Project ImPACT has previously targeted hyperlipidemia and osteoporosis (1"The Pink Sheet" March 30, 1998, p. 20). Support for the depression study is provided by Wyeth, manufacturer of the serotonin/norepinephrine reuptake inhibitor Effexor XR (venlafaxine extended-release)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts